Moclobemide (sold as Aurorix and Manerix) is a reversible monoamine oxidase inhibitor (MAOI) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company.

No significant rise in blood pressure occurs when moclobemide is combined with amines such as tyramine containing foods or pressor amine drugs, unlike the older non-selective irreversible MAOIs which cause a severe rise in blood pressure with such combination. Due to the lack of anticholinergic, cardiovascular, cognitive and psychomotor impairments moclobemide is advantageous in the elderly as well as those with cardiovascular disease.

Read more about MoclobemideTherapeutic Uses, Contraindications and Cautions, Side Effects, Overdose, Interactions, Pharmacology, Pharmacokinetics, Animal Toxicology, History

Other articles related to "moclobemide":

Bicyclic Antidepressants - Adverse Effects - General
... Moclobemide may be preferred in the elderly as its pharmacokinetics are not affected by age, is well tolerated by the elderly as well as younger adults, has few serious adverse events, and, in addition, it is ... A new generation of MAOIs has been introduced moclobemide (Manerix), known as a reversible inhibitor of monoamine oxidase A (RIMA), which is as effective as ...
Moclobemide - History
... but with less of the toxicity of the older irreversible compounds moclobemide's discovery and marketing brought the renewed interest in MAOIs due to an absence of ... In 1992 moclobemide was launched onto the world markets ... Moclobemide was the first reversible MAO-A inhibitor to be widely marketed Moclobemide as well as other newer antidepressants such as the SSRIs lead to changes in ...
Smoking Cessation - Methods - Single Medications
... Moclobemide has been tested in heavy dependent smokers against placebo based on the theory that tobacco smoking could be a form of self medicating of major ... Moclobemide was administered for 3 months and then stopped at 6 months follow-up it was found those who had taken moclobemide for 3 months had a much higher ... the difference between the placebo group and the moclobemide group was no longer significant ...